Goldman Sachs downgraded C.R. Bard (NYSE: BCR) from Neutral to Sell and lowered the price target from $99.00 to $95.00. Goldman Sachs noted, "With BCR's FY1 P/E multiple having expanded 11.6% vs. an 8% cut to earnings estimates, we think the market is giving Bard too much credit for acceleration in outer-year revenue/EPS growth.